A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Study Details
Study Description
Brief Summary
This is a multicenter, open-label, phase II clinical study conducted in China. All subjects will receive AK104 in combination with standard treatment regimens or AK104 alone. The primary end points are objective response rate per RECIST1.1 and safety. Secondary end points are progression-free survival and disease control rate.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: AK104+Paclitaxel+Cisplatin/Carboplatin AK104 intravenously(IV) every 3 weeks (Q3W) Paclitaxel 175mg/m2 IV every 3 weeks (Q3W) Cisplatin 50mg/m2 or Carboplatin AUC5 IV every 3 weeks (Q3W) |
Biological: AK104
Subjects will receive AK104 intravenously.
Drug: Paclitaxel
Subjects will receive Paclitaxel intravenously.
Other Names:
Drug: Cisplatin or Carboplatin
Subjects will receive Cisplatin or Carboplatin intravenously.
Other Names:
|
| Experimental: AK104+Bevacizumab+Paclitaxel+Cisplatin/Carboplatin AK104 every 3 weeks (Q3W) Bevacizumab 15mg/kg IV every 3 weeks (Q3W) Paclitaxel 175mg/m2 IV every 3 weeks (Q3W) Cisplatin 50mg/m2 or Carboplatin AUC5 IV every 3 weeks (Q3W) |
Biological: AK104
Subjects will receive AK104 intravenously.
Biological: Bevacizumab
Subjects will receive Bevacizumab intravenously.
Drug: Paclitaxel
Subjects will receive Paclitaxel intravenously.
Other Names:
Drug: Cisplatin or Carboplatin
Subjects will receive Cisplatin or Carboplatin intravenously.
Other Names:
|
| Experimental: AK104 AK104 IV every 2 weeks (Q2W) |
Biological: AK104
Subjects will receive AK104 intravenously.
|
Outcome Measures
Primary Outcome Measures
- AE [From the time of informed consent signed through 90 days after the last dose of AK104]
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment
Secondary Outcome Measures
- Objective response rate (ORR) [Up to 2 years]
The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.
- Duration of response (DoR) [Up to 2 years]
Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.
- Disease control rate (DCR) [Up to 2 years]
The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST Version 1.1.
- Progression-free survival (PFS) [Up to 2 years]
Progression-free survival is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first.
- Overall survival (OS) [Up to 2 years]
Overall survival is defined as the time from the start of treatment with AK104 until death due to any cause.
- Minimum observed concentration (Cmin) of AK104 at steady state [From first dose of AK104 through 30 days after last dose of AK104]
The endpoints for assessment of PK of AK104 include serum concentrations of AK105 at different timepoints after AK104 administration.
- Number of subjects who develop detectable anti-drug antibodies (ADAs) [From first dose of AK104 through 30 days after last dose of AK104]
The immunogenicity of AK104 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).
- Expression of PD-L1 in tumor tissue samples [Baseline (Tumor tissue samples must be provided to the research center or central laboratory prior to initial administration)]
PD-L1 expression will be determined by IHC in the central laboratory.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written and signed informed consent.
-
Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
-
Estimated life expectancy of ≥3 months.
-
Histologically or cytologically confirmed recurrent or metastatic cervical cancer that not appropriate for radical surgical resection and/or radical radiotherapy or chemotherapy.
-
For cohort A and B: The pathological types were squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma. No previous systematic treatment for recurrent or metastatic cervical cancer.
-
For cohort C: The pathological types were squamous cell carcinoma or adenosquamous cell carcinoma. Subjects must have received platinum-containing dual-drug chemotherapy combination with bevacizumab during or after the recurrence or metastasis phase and have demonstrated radiologically confirmed disease progression during or after treatment. Subjects will have no more than 2 lines of systemic therapy in the recurrence or metastatic stages.
-
Subjects must have at least one measurable lesion in accordance with RECIST v1.1.
-
All subjects must provide archived or freshly acquired tumor tissue samples, approximately 5 unstained FFPE pathological slides.
-
Adequate organ function.
-
Females of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first administration. If having sex with an unsterilized male partner, the subject must use an acceptable contraceptive method since screening and must agree to continue using this contraceptive method for 120 days after the last administration.
Exclusion Criteria:
-
Subjects had clinically significant hydronephrosis that could not be relieved by nephrostomy or urethral stenting, as determined by the investigator.
-
Other active malignancies within 2 years prior to the first administration. Subjects with locally curable tumors that appear to be cured, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the breast, were not excluded.
-
Have received other study drugs or study devices within 4 weeks prior to the first administration.
-
Is participating in another clinical study, unless it is an observational, non-interventional clinical study or a follow-up period for an interventional study.
-
Subjects received systemic treatment with either proprietary Chinese drugs with anti-tumor indications or herbal medicines with anti-tumor effects, or immunomodulatory drugs (thymopeptide, interferon, interleukin) within 2 weeks prior to the first administration.
-
Had received the last course of systemic antitumor therapy within 4 weeks prior to the first administration; Underwent major surgery within 3 weeks; Received non-specific immunoregulatory system treatment within 2 weeks; Any herbal or proprietary Chinese medicine with anti-tumor indications was received within 2 weeks.
-
Have previously received immune checkpoint inhibitors (such as anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.), immune checkpoint agonists (such as antibodies targeting ICOS, CD40, CD137, GITR, and Ox40 targets, etc.), immune cell therapy, etc. Any treatment targeted at the immune mechanism of tumor.
-
Subjects had an active autoimmune disease that required systemic treatment within 2 years prior to the first administration, or an autoimmune disease that was determined by the investigator to be likely to recur or for which treatment was planned.
-
Active or documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis, or chronic diarrhea).Inability to swallow, malabsorption syndrome, or uncontrollable nausea, vomiting, diarrhea or other gastrointestinal disorders that can seriously affect the administration and absorption of drug.
-
Subjects requiring systemic treatment with glucocorticoids (> 10 mg/ day equivalent dose of prednisone) or other immunosuppressive agents within 14 days prior to the first administration.
-
Known history of Immunodeficiency.
-
Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
-
Underwent major surgery or severe trauma within 28 days prior to the first administration; Underwent surgery to improve or reduce the risk of tumor complications within 14 days prior to the first administration; Or have not fully recovered from previous surgery. Significant surgery is planned within 30 days after the first administration (as determined by the investigator).
-
Medical history of gastrointestinal perforation, gastrointestinal fistula, and female reproductive tract fistula within 6 months prior to the first administration; If the perforation or fistula has been treated by excision or repair and the disease has been recovered or remitted as determined by the investigator, admission is allowed.
-
Known history of interstitial lung disease.
-
Known history of active tuberculosis (TB).
-
Serious infections within 4 weeks prior to the first administration, including but not limited to complications requiring hospitalization, sepsis or severe pneumonia.
-
An active infection requiring systemic therapy.
-
Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 1000 IU/ mL or active hepatitis C virus (HCV) should be excluded. Subjects with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA <1000 IU/ mL) , and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only if the HCV RNA test results are negative.
-
Known history of testing positive for human immunodeficiency virus (HIV).
-
Metastases of the central nervous system, metastases of pia mater, spinal cord compression, or pia mater disease confirmed by imaging or pathological examination.
-
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
-
Clinically active hemoptysis, active diverticulitis, peritoneal abscess, or gastrointestinal obstruction.
-
Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria.
-
Grade ≥2 peripheral nerve disease, defined according to the NCI CTCAE V5.0 standard.
-
Receipt of live or attenuated vaccination within 30 days prior to the first administration, or plan to receive live or attenuated vaccine during the study.
-
Known history of serious hypersensitivity reaction to other monoclonal antibodies.
-
Subjects with known contraindications to cisplatin/carboplatin, paclitaxel and bevacizumab or a history of allergy/hypersensitivity to any of their components (refer to the relevant drug label, not applicable for Cohort C, bevacizumab-related contraindications and allergy to bevacizumab only to Cohort B).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hunan Cancer Hospital | Changsha | Hunan | China | 410013 |
| 2 | Zhejiang Cancer Hospital | Hangzhou | Zhejiang | China | 310022 |
Sponsors and Collaborators
- Akeso
Investigators
- Principal Investigator: Jing Wang, MD, Hunan Cancer Hospital
- Principal Investigator: Hanmei Lou, Zhejiang Cancer Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AK104-210